Genomic diagnostics is revolutionizing disease management and forms the cornerstone of precision medicine. This review details the multi-stage operational process of genomic testing, encompassing patient counseling, sample logistics, high-throughput sequencing, bioinformatics pipelines, and clinical interpretation. We examine stringent global regulatory frameworks, including the U.S. FDA, European EMA, and India's CDSCO, which ensure quality and market authorization. Despite technological advancements, significant implementation challenges remain. These include a shortage of trained computational biologists and genetic counselors, the complexities of Electronic Health Record integration, and the requirement for robust quality management systems. Economically, high upfront costs and evolving reimbursement policies present further hurdles. Additionally, the paper addresses critical ethical, legal, and social implications, such as data privacy under India's DPDP Act, informed consent, and the management of secondary findings. The review also highlights the pivotal role of India's private sector and government initiatives like the Genome India Project in building foundational infrastructure. Collectively, these efforts suggest a promising future for personalized prevention and treatment. By synthesizing the scientific, clinical, and commercial facets of genomic diagnostics, this resource provides a comprehensive overview for stakeholders navigating this multifaceted landscape.
Dammalli et al. (Mon,) studied this question.